Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137025 | 0.86 | F2RL3 (0.51) | F2RL3MEN1KMT2AHPGDRORC | |
| SCHEMBL6137351 | 0.68 | RORC (0.50) | F2RL3ALDH1A1HPGDRORCHSD17B10 | |
| SCHEMBL6136810 | 0.68 | ALDH1A1 (0.54) | F2RL3MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4872950 | 0.67 | SMN1; SMN2 (0.54) | KMT2AHPGDSMN1; SMN2KDM4EMAPT | |
| SCHEMBL13455758 | 0.66 | SMN1; SMN2 (0.44) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2346908 | 0.65 | CYP3A4 (0.61) | MEN1KMT2ASNCAALDH1A1SMN1; SMN2 | |
| SCHEMBL16797199 | 0.65 | F2RL3 (0.54) | F2RL3MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL461801 | 0.65 | SNCA (0.61) | MEN1KMT2ASNCAALDH1A1KDM4E | |
| SCHEMBL300884 | 0.65 | CA12 (0.42) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6136775 | 0.64 | RORC (0.57) | HPGDSMN1; SMN2RORCMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED | 2005-10-13 | — | — | US | disclosed |
| EP-1140856-B1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2005-04-27 | — | — | EP | disclosed |
| EP-1140856-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED (AT) | 2001-06-28 | — | — | US | disclosed |
| WO-2000037448-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLC43A1, CUTA, ANXA1 | F2RL3 4196/4885MEN1 2066/4885KMT2A 3039/4885 |
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLCO1A2, ABCG2, SLCO1B1 | F2RL3 2995/4885MEN1 2470/4885KMT2A 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.